BCM
INBX icon

Bluefin Capital Management’s Inhibrx INBX Stock Holding History

Bluefin Capital Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,408
Closed -$160K – 154
2025
Q1 		$160K Buy
+11,408
New +$155K 0.12% 71
2024
Q3 		$289K Sell
18,475
-14,800
-44% -$208K 0.09% 67
2024
Q2 		$472K Buy
+33,275
New +$520K 0.11% 51

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bluefin Capital Management's INBX Position: Q2 2025 in Review

Bluefin Capital Management sold out of Inhibrx (INBX) in Q2 2025, closing a stake of 11,408 shares — an estimated $160K sold.

Bluefin Capital Management first reported a position in INBX in Q2 2024 and held it in 3 quarters. The position peaked at $472K in Q2 2024. 88 funds tracked by Wall St. Rank hold INBX as of Q2 2025.

  • Bluefin Capital Management reported no remaining Inhibrx position as of Q2 2025 after selling out during the quarter.
  • Bluefin Capital Management sold 11,408 Inhibrx shares in Q2 2025, an estimated $160K.
  • Bluefin Capital Management first reported a position in Inhibrx in Q2 2024 and held it in 3 quarters.
  • Bluefin Capital Management's Inhibrx position peaked at $472K in Q2 2024.
  • 88 funds tracked by Wall St. Rank held Inhibrx as of Q2 2025.

Based on Bluefin Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.